Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1974 2
1979 1
1981 4
1982 6
1983 2
1984 3
1985 4
1986 4
1987 4
1988 1
1990 2
1992 2
1993 5
1995 5
1996 5
1997 1
1998 6
1999 2
2000 2
2001 2
2002 4
2007 1
2008 1
2010 3
2011 1
2012 3
2013 6
2015 4
2016 3
2018 3
2020 2
2021 1
2023 1
2024 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

94 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial.
McInnes IB, Kavanaugh A, Gottlieb AB, Puig L, Rahman P, Ritchlin C, Brodmerkel C, Li S, Wang Y, Mendelsohn AM, Doyle MK; PSUMMIT 1 Study Group. McInnes IB, et al. Lancet. 2013 Aug 31;382(9894):780-9. doi: 10.1016/S0140-6736(13)60594-2. Epub 2013 Jun 13. Lancet. 2013. PMID: 23769296 Clinical Trial.
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2).
Papp KA, Langley RG, Lebwohl M, Krueger GG, Szapary P, Yeilding N, Guzzo C, Hsu MC, Wang Y, Li S, Dooley LT, Reich K; PHOENIX 2 study investigators. Papp KA, et al. Lancet. 2008 May 17;371(9625):1675-84. doi: 10.1016/S0140-6736(08)60726-6. Lancet. 2008. PMID: 18486740 Clinical Trial.
Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials.
Griffiths CE, Reich K, Lebwohl M, van de Kerkhof P, Paul C, Menter A, Cameron GS, Erickson J, Zhang L, Secrest RJ, Ball S, Braun DK, Osuntokun OO, Heffernan MP, Nickoloff BJ, Papp K; UNCOVER-2 and UNCOVER-3 investigators. Griffiths CE, et al. Lancet. 2015 Aug 8;386(9993):541-51. doi: 10.1016/S0140-6736(15)60125-8. Epub 2015 Jun 10. Lancet. 2015. PMID: 26072109 Clinical Trial.
Advances in forefoot trauma.
Clements JR, Schopf R. Clements JR, et al. Among authors: schopf r. Clin Podiatr Med Surg. 2013 Jul;30(3):435-44. doi: 10.1016/j.cpm.2013.04.005. Clin Podiatr Med Surg. 2013. PMID: 23827495 Review.
IDEC-114 (IDEC).
Schopf RE. Schopf RE. Curr Opin Investig Drugs. 2001 May;2(5):635-8. Curr Opin Investig Drugs. 2001. PMID: 11569938 Review.
Pimecrolimus (Novartis).
Schopf RE. Schopf RE. IDrugs. 1999 Nov;2(11):1197-200. IDrugs. 1999. PMID: 16113991
[Biliodigestive fistulas].
Schöpf R. Schöpf R. Rofo. 1979 Jan;130(1):112-3. doi: 10.1055/s-0029-1231235. Rofo. 1979. PMID: 153297 German. No abstract available.
Pimecrolimus. Novartis.
Schopf RE. Schopf RE. Curr Opin Investig Drugs. 2002 May;3(5):720-4. Curr Opin Investig Drugs. 2002. PMID: 12090545
94 results